Becton Dickinson (BDX) stock
Health Care · Health Care Equipment
Becton Dickinson (BDX) is a Health Care Equipment company in the Health Care sector, headquartered in Franklin Lakes, New Jersey. As of October 23, 2026, BDX closed at $198.91, a market capitalization of $54.18 billion, the 221st largest company in the S&P 500. Over the last twelve months it generated $22.48 billion in revenue (+5% year over year) and $2.53 billion in free cash flow. The stock trades at 46.3x trailing earnings and 15.0x forward earnings.
- 1-year total return: +39.0% (dividends reinvested)
- 5-year return: +2.8% a year
- 52-week range: $127.59 – $200.47
- Gross margin 46.9%, operating margin 15.7%
- Dividend yield: 2.11%, 42 straight years of increases
- FI Handbook report card: C+ across 10 metrics
- 27th largest of 60 Health Care stocks in the S&P 500
BDX price chart
1Y price change: +35.6% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| BDX | +9.0% | +32.9% | +39.0% | +1.7% | +2.8% | +5.8% | +10.7% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1973.
BDX key statistics
- Market cap
- $54.2B
- #221 in S&P 500
- P/E (TTM)
- 46.3x
- Forward P/E
- 15.0x
- EPS (TTM)
- $4.30
- Revenue (TTM)
- $22.5B
- +5%
- Free cash flow
- $2.5B
- Gross margin
- 46.9%
- Operating margin
- 15.7%
- Return on equity
- 6.6%
- Dividend yield
- 2.11%
- 52-week range
- $127.59 – $200.47
- Beta
- 0.28
- Price / sales
- 2.4x
- EV / EBITDA
- 11.5x
- Debt / equity
- 0.69x
- Employees
- 72,000
BDX report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.4%C
- Gross margin46.9%B
- Operating margin15.7%C
- FCF margin11.3%C
- Return on equity6.6%D
- Net debt / EBITDA2.6xD
- Forward P/E15.0xA
- PEG ratio1.1xB
- Shareholder yield4.0%B
- Share count change / yr0.4%C
Becton, Dickinson and financials
Revenue went from $12.5B in fiscal 2016 to $21.8B in fiscal 2025, growing 6.4% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5B | $12.1B | $16.0B | $17.3B | $16.1B | $19.1B | $18.9B | $19.4B | $20.2B | $21.8B |
| Gross profit | $6.0B | $5.9B | $7.3B | $8.3B | $7.6B | $8.6B | $8.5B | $8.2B | $9.1B | $9.9B |
| Operating income | $1.4B | $1.5B | $1.5B | $1.8B | $912.0M | $2.3B | $2.3B | $2.1B | $2.4B | $2.6B |
| Net income | $976.0M | $1.1B | $311.0M | $1.2B | $874.0M | $2.1B | $1.8B | $1.5B | $1.7B | $1.7B |
| EPS (diluted) | $3.44 | $3.53 | $0.46 | $3.02 | $2.13 | $5.39 | $4.62 | $3.88 | $4.61 | $4.58 |
| Free cash flow | $1.9B | $1.8B | $2.0B | $2.4B | $2.8B | $3.5B | — | — | — | — |
| Buybacks | $0 | $220.0M | $0 | $0 | $0 | $1.8B | $500.0M | $0 | $500.0M | $1.0B |
| Dividends paid | $562.0M | $677.0M | $927.0M | $984.0M | $1.0B | $1.0B | $1.1B | $1.1B | $1.1B | $1.2B |
| Diluted shares | 283.6M | 291.5M | 345.0M | 358.3M | 359.2M | 371.5M | 365.5M | 366.8M | 370.2M | 367.0M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into BDX?
A reverse DCF asks what growth the current price requires. With an enterprise value of $70.3B and $2.5B of trailing free cash flow, Becton, Dickinson and needs to grow free cash flow about 18.9% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 13.1% a year over the last five years.
P/E ratio history
Current 43.5x vs. median 35.7x (10th–90th percentile 14.4x–85.1x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
BDX dividend
- Dividend yield
- 2.11%
- Annual dividend
- $4.20
- Years of increases
- 42
- 5-yr dividend growth
- 6.0%
- per year
- Payout ratio
- 72%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
BDX analyst price targets
14 analysts' average 12-month target is $195.57 (-2% vs. $198.91). Targets range from $165.00 to $225.00. 50% rate it a buy.
BDX earnings
Next report: November 5, 2026. Becton, Dickinson and has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $5.0B (+5% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 6, 2026 | $3.14 | $3.23 | +2.9% |
| May 7, 2026 | $2.77 | $2.90 | +4.5% |
| Feb 9, 2026 | $2.81 | $2.91 | +3.5% |
| Nov 6, 2025 | $3.91 | $3.96 | +1.1% |
| Aug 7, 2025 | $3.40 | $3.68 | +8.2% |
| May 1, 2025 | $3.28 | $3.35 | +2.1% |
| Feb 5, 2025 | $2.99 | $3.43 | +14.7% |
| Nov 7, 2024 | $3.77 | $3.81 | +1.1% |
Stocks like BDX
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BSX Boston Scientific | -0.70% | -55% | $66.2B | 18.5x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
 RMD ResMed | -0.08% | -4% | $35.6B | 24.2x | Compare |
BDX news
- What Becton Dickinson Stock's New U.S. Manufacturing Deal Means For Shareholders · Oct 23, 2026
- Becton Dickinson (BDX) Stock Trades Below Fair Value After A 40% Run · Oct 23, 2026
- Is Becton Dickinson (BDX) Fully Priced As Execution Improves Before Earnings? · Oct 23, 2026
- BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? · Oct 22, 2026
- BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients · Oct 15, 2026
BDX stock FAQ
What is BDX's market cap?
Becton Dickinson's market capitalization is $54.18 billion as of October 23, 2026, ranking 221st in the S&P 500.
What is BDX's P/E ratio?
BDX trades at a trailing price-to-earnings ratio of 46.3x and a forward P/E of 15.0x. Its median P/E over the period we track is 35.7x.
Does BDX pay a dividend?
Yes. Becton Dickinson pays $4.20 per share a year, a 2.11% yield. It has raised its dividend 42 years in a row. Dividends grew 6.0% a year over the last five years.
How much has BDX stock returned?
Including reinvested dividends, BDX returned +39.0% over one year, +2.8% a year over five years, +5.8% a year over ten years through October 23, 2026.
Is BDX stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Becton Dickinson must grow free cash flow about 19% a year for the next decade. Its free cash flow grew 13% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the BDX price target?
14 analysts cover BDX with an average 12-month price target of $195.57, -2% from the current price. 50% of them rate it a buy.
When does BDX report earnings?
Becton Dickinson is expected to report earnings on November 5, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Becton Dickinson have?
Becton Dickinson has about 72,000 full-time employees, or $312,278 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology